Mis-Reading the Minutes: Arena Approval Follows Sell-Off Based on Advisory Committee Summary
This article was originally published in RPM Report
Executive Summary
Arena received great news June 27: approval of the weight loss therapy Belviq with a very clean label and no special marketing restrictions. That was what Wall Street expected—except when investors read the summary of the advisory committee review of the drug published by FDA on June 22.